Latest Drugwonks' Blog

Tech Support

  • 05.09.2006

Study: Number of Drugs Entering Testing Up

The number of drugs that entered clinical testing surged 52 percent in the three years ended in 2005, signaling the pharmaceutical industry may be emerging from its research and development drought, according to a new study by the Tufts Center for the Study of Drug Development.

The increase represents a jump from the 21 percent decline in medicines entering testing in the five years ended in 2002 from the five-year period ended in 1997, according to a study of 10 pharmaceutical makers

According to the Center the improvement seen in the recent study is a result of new technologies that enable scientists to better judge a drug candidate’s likelihood of success and an increase in products licensed from other companies.

If you’ve heard that one, try this —

The Washington Post story on Trovan in Nigeria conveniently fails to include several pertinent facts, underscoring the victory of headlines over facts.

For example, the article claims that “… the panel said an oral form of Trovan, the Pfizer drug used in the test, had apparently never been given to children with meningitis.”

In fact,while Trovan had never been used in children with meningitis, other antbiotics of the flouroquinolones class had been tested in children with that disease with success.

Here is a summary of one such study ( Ciprofloxacin in preterm neonates: case report and review of the literature. van den Oever HL, Versteegh FG, Thewessen EA, van den Anker JN, Mouton JW, Neijens HJ. Eur J Pediatr. 1998 Oct;157(10):843-5.)

The article also implies that the Trovan trial did nothing to help address the epidemic of meningitis in Nigeria.

Despite optimal therapy, meningococcal meningitis has a 10% fatality rate and at least 15% central nervous system damage. The Post continues to ignore the fact that Pfizer’s treatment resulted in the best survival rate of any treatment then being administered in Kano. While Doctors Without Borders (DWB) treated patients with epidemic meningitis in Kano with a different medication, oily chloramphenicol, which was not approved for use in Nigeria, and succeeded in lowering the death rate to approximately 9.1 percent, Pfizer lowered the mortality rate even further to 6 percent. The rate was the same for the group who were administered Trovan and the group who received the other antibiotic that Pfizer supplied. Pfizer’s rate was also lower than the overall rate for the epidemic which ranged from 10-30 percent.

Nearly 50-100 percent reduction in mortality and Pfizer was ignoring the problem?

Finally, the head of the Nigerian “commission” who did the study has his own problems …

Dr Abdulsalami Nasidi, who chaired the commision looking at the Pfizer conduct is also head of an umbrella body for anti-AIDS groups and government agencies in Nigeria. It turns out that the his group was asking AIDS patients to pay for their drugs, which it got free. Medicins Sans Frontieres’ found nearly half of people on drug treatment in Nigeria did not receive sufficient doses due to lack of funds.

The Post fails to note that Nasidi had opposed the Pfizer trial from the outset. Moreover, the Post failed to discuss the fact that two factions in Nigeria were at war over the trial and that many observers claimed (it’s in the report the Post had) that Pfizer knew it was not wanted in Nigeria…. Indeed it is clear from the report that Pfizer was caught in the crossfire of a political feud and that much of the “testimony” regarding the handling of the study is of the “he-said, she-said” variety with one group saying the trial was conducted properly (those supporting use of Trovan) and those saying it was not (those who opposed the trial from the outset). Yet the Post story reads as if the report consistently slams Pfizer and the researchers.

It doesn’t.

And just last week The Global Fund against AIDS, Tuberculosis and Malaria at the weekend halted US $50 million in grants to Nigeria, citing the country’s failure to meet performance targets.

Fund spokesman Jon Liden said the governing board voted to suspend payment on two five-year grants after just two years because Nigeria had missed targets on anti-AIDS treatment access and other goals.

So let’s see, Nasidi is both the chair of this commission and of the AIDs group criticized for selling drugs it got for free and for missing performance targets.

Nothing like attacking a big, bad pharma company to divert attention from your own incompetence.

The Washington Post got played.

Here’s a great op-ed about how politics is undermining the FDA and medical progress …

Wrongly Blaming The FDA

By William Hubbard
Monday, May 8, 2006; Page A19

Last month the Government Accountability Office released another report criticizing the Food and Drug Administration’s efforts to ensure the safety of prescription drugs. It seems to have become great sport for public officials to revel in FDA shortcomings. Time after time in recent years, FDA scientists have warned of threats to the safety of the nation’s food and drugs, sought new resources and tools to deal with those threats, and been duly dismissed. Yet when their predictions have come true, decision makers of all political stripes rush to bemoan the agency’s failures …

The rest of op-ed can be found here

http://www.washingtonpost.com/wp-dyn/content/article/2006/05/07/AR2006050700907.html

Magic Marker

  • 05.08.2006

Magic marker? Anyting but. It’s science baby!

And that’s why the Path is Critical.

(As a 40-something male this one really strikes close to home.)

Here’s the news

Scientists are reporting that they have detected a variant gene associated with prostate cancer, a finding that may make possible a diagnostic test to help decide which patients are the best candidates for aggressive treatment. The discovery by Decode Genetics, a gene-finding company based in Iceland, may also help explain why African-Americans, in whom the variant is more common, have a greater incidence of the disease.

Here’s a link to the rest of the story …

http://www.nytimes.com/2006/05/07/health/menshealth/07cnd-prostate.html?adxnnl=1adxnnlx=1147049376-ZOSKtUI+AQ83eCJGvmqAQ

Medicare 2.0

  • 05.07.2006

Soild reporting in today’s LA Times on the current state of affairs surrounding Part D. Here’s a link:

http://www.latimes.com/news/printedition/front/la-na-medicare7may07,1,5331765.story?coll=la-headlines-frontpage

And here are a few of my favorite paragraphs …

WASHINGTON — With the first enrollment deadline a week away, the Medicare prescription benefit apparently is achieving its primary objective: helping millions of Americans get protection they did not previously have against one of the most draining problems of growing older.

By the May 15 deadline, federal officials expect to have more than 20 million seniors enrolled in plans under Medicare Part D, as the benefit program is called. That would include at least 7 million who previously lacked insurance for outpatient prescriptions. Of the millions who have signed up, many are enjoying significant savings, sometimes $1,000 a year or more.

And the performance of the drug plan, offered through private insurers, goes well beyond benefits for today’s seniors. The plan is a test of Bush’s idea that, instead of creating new federal bureaucracies, Washington can use businesses, informed consumers and market competition to solve knotty social problems such as access to healthcare — potentially for all Americans.

“This is the first full test of competition in Medicare,” said Joseph Antos, a health policy expert at the American Enterprise Institute, a conservative think tank. “It’s also a test of consumerism in healthcare.”

Medicare Administrator Mark McClellan said he had been working to make the program more user-friendly, and he pointed to a string of recent agency actions.

They include a directive limiting the ability of insurers to force patients to switch drugs; a standard appeals form doctors can use when a patient is denied a medication; and a set of common computer codes for pharmacists to communicate more easily with drug plans.

Around Health and Human Services headquarters in Washington, the new buzzword is “Version 2.0.” Next year’s Medicare drug benefit will feature fewer plans and better benefits, Leavitt said.

“We will see Medicare Version 2.0 much informed by what we have learned in Version 1.0,” he said.

The WSJ claims that the $40 billion in uncompensated care (75 percent of which is paid for by tax dollars) is only 2.4 percent of total health care spending. A better, more honest denominator is the percentage of total benefits paid by private health insurance premiums or total public health expenditures (which would make it more like 8 percent). But in any event, providing coverage would probably drive up total health care spending overall. But is that an argument for not insuring people? Second,what about the social gain of having people covered?

Conservative are grousing about the community rating and cost of premiums like it’s something that can’t change. Why not do what liberals do and grind away to make RomneyCare and other efforts better? What about conservative claims that CDHC plans are controlling premium increases and encouraging preventive care.

I cannot believe how churlish and intellectually sloppy the response to Governor Romney’s plan has been. If we had reacted this way to Medicare where would we be today?

Parklawn Penseurs

  • 05.05.2006

Here’s a link to the May 2006 cover story of Medical Marketing & Media, “FDA at 100.”

FDA at 100: Alumni take its temperature

It features interviews with an eclectic collection of former FDA senior officials including the talented Dan Troy, “Mr. PDUFA” Marc Scheineson, a grinning Wayne Pines, the quixotic Andrea Kupchyk, Susan “What do I do now?” Wood, and me.

The article delivers what it promises, Parklawn insights — some more insightful than others — through the eyes of six insiders who share a medley of interesting, angering, important, gossipy and, yes, even score-settling comments.

Here’s to the FDA’s second hundred years of protecting and advancing America’s health — with a confimed Commissioner.

SchadenFDAude

  • 05.04.2006

SchadenFDAude. noun. Pleasure derived from the misfortunes of the FDA.

Unfortunately it applies to a lot of people (in politics, the media, the public policy world, and even former FDA officials) who would rather enjoy the pleasure than work collectively and collegially to help solve the problem.

Need I name names?

Yesterday NRO posted a beside-the-point editorial by Henry Miller who once again recycled his assertion that all the FDA needs is a strong commander who will kick the asses of drug reviewers who fail to approve new medicines as fast as possible.

http://article.nationalreview.com/?q=YWU5M2MzY2JhODM4M2QyZDljODJiOWMxZTcxMzNjY2Y=

His attacks have no substance and are actually recycled from news articles written by journalists like Alicia Mundy — who is also a fellow at the Soros funded New America Foundation — and ad homimen attacks from people like Donald Kennedy, the last FDA Commissioner to smoke. Miller dredges up the media invented charge that Gottlieb’s appointment is unusual because he had no medical experience. Miller knows better: Gottlieb still sees patients and has been doing so for years. And Miller’s attacks on Andy von Eschenbach and Janet Woodcock are purely second hand.

Has Henry never heard of surrogate endpoints and biomarkers. And does he really believe that the FDA is fully responsible for the decline in new drug approvals? How about poorly validated targets? How about the fact that companies often withdraw drugs after Phase III? He tosses out a laundry list of FDA problems and ignores the efforts of the three people he attacked to undo them with better science and better oversight. To simply say that only leadership matters is to ignore the fact that scientific change is an important tool for forcing change at the FDA and moving the agency away from being risk averse. Had he had read the Critical Path opportunities list? Does he really think that outdate methods of drug evaluation don’t need to be changed? Is anything going on inside Miler’s mind in this regard beyond chatty assaults?

PAP Smear?

  • 05.03.2006

GlaxoSmithKline has announced that elderly and disabled patients who are eligible for Medicare drug benefits that took effect Jan. 1 will not lose the ability to get free drugs under the company’s patient assistant programs. In December, GSK notified patients eligible for Medicare D that they would not qualify for the free drug programs after May 15.

“The Medicare prescription drug benefit is a valuable program for millions of Americans, but we recognize that there are many elderly and disabled low-income patients who need additional help,” said Chris Viehbacher, GSK’s president of U.S. pharmaceuticals.

GSK plans to ask the federal government for an opinion whether patients enrolled in Medicare D can also participate in patient assistant programs.

For now, eligible patients must opt out of Medicare D to participate in GSK’s free drug programs.

About 200,000 of the 565,000 patients in GSK’s free drug programs are eligible for Medicare D.

Dicey TrOOP implications here. Stay tuned.

CMPI

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog